Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update
Timothy P. Hughes, Nelma Cristina D. Clementino, Mikhail Fominykh, Jeffrey H. Lipton, Anna Turkina, Elena Beatriz Moiraghi, Franck E. Nicolini, Naoto Takahashi, Tomasz Sacha, Dong‐Wook Kim, Rafik Fellague-Chebra, Ranjan Tiwari, Catherine Bouard, François-Xavier Mahon
Topics & Concepts
NilotinibMedicineMyeloid leukemiaInternal medicineAdverse effectTyrosine-kinase inhibitorImatinibSurgeryCancerChronic Myeloid Leukemia TreatmentsEosinophilic Disorders and SyndromesChemotherapy-induced cardiotoxicity and mitigation